IMMUNOVEDA Trademark

Trademark Overview


On Thursday, June 1, 2023, a trademark application was filed for IMMUNOVEDA with the United States Patent and Trademark Office. The USPTO has given the IMMUNOVEDA trademark a serial number of 98023632. The federal status of this trademark filing is REGISTERED as of Tuesday, June 18, 2024. This trademark is owned by Genesis Drug, Discovery & Development, LLC. The IMMUNOVEDA trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Medical research services in the field of cancer; Medical and scientific research in the field of cancer treatment and diagnosis; Providing laboratory research services in the field of gene expression, namely, cancer biology
immunoveda

General Information


Serial Number98023632
Word MarkIMMUNOVEDA
Filing DateThursday, June 1, 2023
Status700 - REGISTERED
Status DateTuesday, June 18, 2024
Registration Number7420266
Registration DateTuesday, June 18, 2024
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, April 2, 2024

Trademark Statements


Description of MarkThe mark consists of the word "IMMUNOVEDA" in purple, above the letter "I" is a purple dot; starting from this first dot is series of gradient purple to blue dots with each dot getting smaller in size and lighter in contrast to the first dot, and the space between the dots increases as the dots sweep upward in a curve toward the top of the mark, creating a band of dots, reaching an apex whereupon they descend in a curve toward the letter "A", upon reaching the letter "A" in one single dot whereupon they end. The color white represents background and transparent areas and is not part of the mark.
Indication of Colors claimedThe color(s) blue and purple is/are claimed as a feature of the mark.
Goods and ServicesResearch and development of pharmaceuticals for the treatment of age-related diseases and cancer; Medical research services in the field of cancer; Medical and scientific research in the field of cancer treatment and diagnosis; Providing laboratory research services in the field of gene expression, namely, cancer biology

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, July 6, 2023
Primary Code042
First Use Anywhere DateSaturday, October 31, 2020
First Use In Commerce DateSaturday, October 31, 2020

Trademark Owner History


Party NameGenesis Drug, Discovery & Development, LLC
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressHamilton, NJ 08690

Party NameGenesis Drug, Discovery & Development, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressHamilton, NJ 08690

Party NameGenesis Drug, Discovery & Development, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressHamilton, NJ 08690

Trademark Events


Event DateEvent Description
Monday, June 5, 2023NEW APPLICATION ENTERED
Friday, July 7, 2023NOTICE OF DESIGN SEARCH CODE E-MAILED
Friday, September 15, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, September 15, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Friday, September 15, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, February 23, 2024ASSIGNED TO EXAMINER
Friday, February 23, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, July 6, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, September 15, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, March 13, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 2, 2024PUBLISHED FOR OPPOSITION
Tuesday, April 2, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 18, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, June 18, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED